This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shionogi Inc. ( Shionogi )
ClinicalTrials.gov Identifier:
NCT01122030
First received: May 10, 2010
Last updated: April 19, 2017
Last verified: September 2011
  Purpose
The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.

Condition Intervention Phase
Opioid Induced Bowel Dysfunction Drug: Naldemedine Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Resource links provided by NLM:


Further study details as provided by Shionogi Inc. ( Shionogi ):

Primary Outcome Measures:
  • Number of Participants With Adverse Events [ Time Frame: From the first dose of study drug on Day 15 up to Day 24. ]

    Severity of adverse events (AEs) was graded according to the following definitions:

    • Mild: The subject experiences awareness of symptoms but these are easily tolerated or managed without specific treatment
    • Moderate: The subject experiences discomfort enough to cause interference with usual activity, and/or the condition requires specific treatment
    • Severe: The subject is incapacitated with inability to work or do usual activity, and/or the event requires significant treatment measures.

    The relationship of the event to the study drug was determined by the investigator.

    A serious adverse event (SAE) is defined as any AE occurring at any dose that resulted in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.



Secondary Outcome Measures:
  • Change From Baseline to 24 Hours Post-dose in Number of Spontaneous Bowel Movements (SBMs) Per Day [ Time Frame: Baseline (Day 1 to Day 15) and Day 15 to 16 (0 to 24 hours post-dose) ]

    Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement.

    Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).


  • Change From Baseline to 48 Hours Post-dose in the Number of SBMs Per Day [ Time Frame: Baseline (Day 1 to Day 15) and Day 15 to Day 17 (0 to 48 hours post-dose) ]
    Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of SBMs per day from 0 to 48 hours post-dose.

  • Change From Baseline to 24 Hours Post-dose in Number of Bowel Movements (BM) Per Day [ Time Frame: Baseline and 24 hours post-dose ]
    Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).

  • Change From Baseline to 48 Hours Post-dose in Number of Bowel Movements Per Day [ Time Frame: Baseline and 48 hours post-dose ]
    Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of BMs per day from 0 to 48 hours post-dose.

  • Change From Baseline to 24 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day [ Time Frame: Baseline and 24 hours post-dose ]

    Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of "having a feeling of complete emptying after the bowel movement").

    Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).


  • Change From Baseline to 48 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day [ Time Frame: Baseline and 48 hours post-dose ]

    Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of "having a feeling of complete emptying after the bowel movement").

    Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of CSBMs per day from 0 to 48 hours post-dose.


  • Time to First Spontaneous Bowel Movement [ Time Frame: From first dose on Day 15 through Day 17 ]
    The time to first SBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant's first SBM was counted as an event and the time to first SBM after dosing was calculated from the date and time of first dosing until the date and time of first SBM. Participants who dropped out or were lost to follow-up before the first SBM were censored.

  • Time to First Bowel Movement [ Time Frame: From first dose on Day 15 through Day 17 ]
    The time to first BM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant's first BM was counted as an event and the time to first BM after dosing was calculated from the date and time of first dosing until the date and time of first BM. Participants who dropped out or were lost to follow-up before the first BM were censored.

  • Time to First Complete Spontaneous Bowel Movement [ Time Frame: From first dose on Day 15 through Day 17 ]
    The time to first CSBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant's first CSBM was counted as an event and the time to first CSBM after dosing was calculated from the date and time of first dosing until the date and time of first CSBM. Participants who dropped out or were lost to follow-up before the first CSBM were censored.

  • Change From Baseline in Straining During Bowel Movements [ Time Frame: Baseline, 24 hours post-dose and 48 hours post-dose ]

    Straining during BMs was graded using the following scale: 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.

    Baseline was defined as the average straining score of all BMs prior to receiving study drug (Day 1 to Day 15). The straining score at 24 and 48 hours post-dose was calculated as the average straining score from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.


  • Change From Baseline to 24 Hours Post-dose in Number of Complete Bowel Movements Per Day [ Time Frame: Baseline and 24 hours post-dose ]
    A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question "Did you have a feeling of complete emptying after the bowel movement?" Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to Day 15).

  • Change From Baseline to 48 Hours Post-dose in Number of Complete Bowel Movements Per Day [ Time Frame: Baseline and 48 hours post-dose ]
    A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question "Did you have a feeling of complete emptying after the bowel movement?" Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to 15). Forty-eight hours post-dose was calculated as the average number of CBMs per day from 0 to 48 hours post-dose.

  • Change From Baseline in Abdominal Bloating [ Time Frame: Baseline, 24 hours post-dose and 48 hours post-dose ]

    Participants were asked to rate their abdominal bloating for the past 24 hours using the following scale:

    0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal bloating score prior to receiving study drug (Day 1 to Day 15). Abdominal bloating at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.


  • Change From Baseline in Abdominal Discomfort [ Time Frame: Baseline, 24 hours post-dose and 48 hours post-dose ]

    Participants were asked to rate their abdominal discomfort for the past 24 hours using the following scale:

    0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal discomfort score prior to receiving study drug (Day 1 to Day 15). Abdominal discomfort at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.


  • Change From Baseline in BM Consistency [ Time Frame: Baseline, 24 hours post-dose and 48 hours post-dose ]

    Consistency of BMs was measured using the Bristol Stool Scale, as follows:

    1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.

    Baseline was defined as the average consistency of BMs prior to receiving study drug (Day 1 to Day 15). BM consistency at 24 hours and 48 hours post-dose was calculated as the average scores from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.


  • Change From Baseline in Number of False Start Bowel Movements Per Day [ Time Frame: Baseline, 24 hours post-dose and 48 hours post-dose ]

    A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted) based on the question "In the past 24 hours, how many times did you try to have a bowel movement but were unsuccessful?" Baseline was defined as the average number of false start BMs per day prior to receiving study drug (Day 1 to Day 15).

    The number of false start BMs per day at 24 hours and 48 hours post-dose was calculated as is the average number of false start BMs per day from 0 to 24 and 0 to 48 hours post-dose, respectively.


  • Change From Baseline in the Number of Bowel Movements With No Straining Per Day [ Time Frame: Baseline, 24 hours post-dose and 48 hours post-dose ]

    Straining during BMs was graded using the following scale:

    0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score = 0.

    Baseline was defined as the average number of BMs without straining per day prior to receiving study drug (Day 1 to Day 15). The number of BMs without straining per day at 24 hours and 48 hours post-dose was calculated as the average number of BMs with no straining per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.


  • Change From Baseline in Number of Rescue Medications Used Per Day [ Time Frame: Baseline, 24 hours post-dose and 48 hours post-dose ]
    Baseline was defined as the average number of rescue medications used per day prior to receiving study drug (Day 1 to Day 15). The number of rescue medications used per day at 24 hours and 48 hours post-dose was calculated as the average number of rescue medications used per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.

  • Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score > 8 at Any Time During the Study [ Time Frame: The COWS assessments were performed at Screening, on Day 14, Day 15 (pre-dose and 1, 2, 3, 4, 5, 6 and 8 hours post-dose, and at unscheduled times as signs or symptoms indicate), on Days 16 and 17, and on Day 24/End of Study. ]
    The COWS assessment consisted of 11 questions which rated the severity of opiate withdrawal symptoms, including resting pulse rate, gastrointestinal upset, sweating, restlessness, pupil size, tremor, anxiety or irritability, bone or joint aches, gooseflesh skin, yawning, and runny nose or tearing. Each symptom was rated on a scale from 0 (not present) to 4 or 5 (most severe). The total score was calculated by summing the 11 individual scores and ranged from 0 (no withdrawal symptoms) to 48 (worst symptoms).

  • Percentage of Participants With Webster Opiate Withdrawal Scale (WOWS) Score > 8 at Any Time During the Study [ Time Frame: The WOWS assessment was performed at Screening, Day 14, Day 15 at pre-dose , and 24 and 48 hours post-dose and at the Follow-up/End of Study visit (Day 24). ]
    The Webster Opiate Withdrawal Scale (WOWS) assessment consisted of 7 questions which rate the severity of opiate withdrawal symptoms, including sweating, sleep, bone or joint aches, runny nose or tearing, gastrointestinal upset, anxiety or irritability and gooseflesh skin. Each symptom was rated on a scale from 0 (not present/no issues) to 4 or 5 (severe). The total score was calculated by summing the 7 individual scores and ranged from 0 (no withdrawal symptoms) to 29 (worst symptoms).

  • Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995 [ Time Frame: Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose. ]
    The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.

  • Time to Maximum Observed Plasma Concentration of Naldemedine and Metabolite Nor-S-297995 [ Time Frame: Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose. ]
    The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.

  • Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration of Naldemedine and Metabolite Nor-S-297995 [ Time Frame: Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose. ]
    The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to the last sampling time at which concentrations were at or above the limit of quantitation, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations (Linear Up/ Log Down).

  • Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Naldemedine and Metabolite Nor-S-297995 [ Time Frame: Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose. ]
    The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to infinity, calculated using the formula: AUC0-inf = AUC0-t + Ct/λZ where Ct was the last measurable concentration and λZ was the apparent terminal elimination rate constant.

  • Apparent Elimination Half-life of Naldemedine and Metabolite Nor-S-297995 [ Time Frame: Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose. ]
    The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. The apparent elimination half-life was calculated using the formula t1/2,z = (ln2)/λZ


Enrollment: 72
Actual Study Start Date: May 19, 2010
Study Completion Date: March 22, 2011
Primary Completion Date: February 23, 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
Drug: Naldemedine
Tablets or solution for oral administration
Other Names:
  • S-297995
  • Symproic®
Drug: Placebo
Tablets or solution for oral administration
Experimental: Cohort 2
In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
Drug: Naldemedine
Tablets or solution for oral administration
Other Names:
  • S-297995
  • Symproic®
Drug: Placebo
Tablets or solution for oral administration
Experimental: Cohort 3
In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
Drug: Naldemedine
Tablets or solution for oral administration
Other Names:
  • S-297995
  • Symproic®
Drug: Placebo
Tablets or solution for oral administration
Experimental: Cohort 4
In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
Drug: Naldemedine
Tablets or solution for oral administration
Other Names:
  • S-297995
  • Symproic®
Drug: Placebo
Tablets or solution for oral administration
Experimental: Cohort 5
In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
Drug: Naldemedine
Tablets or solution for oral administration
Other Names:
  • S-297995
  • Symproic®
Drug: Placebo
Tablets or solution for oral administration
Experimental: Cohort 6
In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
Drug: Naldemedine
Tablets or solution for oral administration
Other Names:
  • S-297995
  • Symproic®
Drug: Placebo
Tablets or solution for oral administration

Detailed Description:
A single dose of naldemedine or matching placebo will be administered orally to each cohort of 12 participants (9 treatments, 3 placebos) in the morning of Day 15 under fasted conditions. The first cohort will receive a 0.1 mg dose. Cohorts will continue to be enrolled at the next higher dose level until the highest dose level (3 mg) has been achieved or until the study is discontinued due to adverse events or Clinical Opioid Withdrawal Score of >8. A 0.03 mg dose will also be tested. A 0.01 mg dose will be tested if 4 or more subjects experience 1 or more bowel movements within the 24 hour period post dose in the 0.03 mg dosing cohort.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Understand and sign an informed consent form
  • Males will agree to use an approved double-barrier method of contraception from Day 1 until 1 month after study completion
  • Subject tests negative on urine drug test unless the subject has a prescription for the drug(s) that test positive

Exclusion Criteria:

  • Subjects under opioid therapy for cancer-related pain or for the management of drug addiction
  • Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other active medical disorders associated with diarrhea, intermittent loose stools, or constipation
  • Subjects who have participated in any other investigational drug study within 30 days prior to Day 1
  • Prior exposure to S-297995
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01122030

Locations
United States, Utah
Shionogi Research Site
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Shionogi
Investigators
Study Director: Shionogi Clinical Trials Administrator Clinical Support Help Line Shionogi
  More Information

Responsible Party: Shionogi
ClinicalTrials.gov Identifier: NCT01122030     History of Changes
Other Study ID Numbers: 1007V9214
Study First Received: May 10, 2010
Results First Received: April 19, 2017
Last Updated: April 19, 2017

Keywords provided by Shionogi Inc. ( Shionogi ):
Chronic pain
Opioid physical dependence

Additional relevant MeSH terms:
Chronic Pain
Intestinal Diseases
Gastrointestinal Diseases
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Digestive System Diseases
Pharmaceutical Solutions
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on June 27, 2017